Filing Analysis
📢 Regulation FD Disclosure
Filed May 13, 2026
⚪ LOW
Cytosorbents Corporation announced its financial results for the first quarter ended March 31, 2026. The disclosure was made through a press release furnished as an exhibit to the filing.
📋 Key Facts
- The company reported financial results for the quarter ended March 31, 2026, on May 13, 2026.
- The results were disclosed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the performance was included as Exhibit 99.1.
⚠️ Delisting Notice
Filed Apr 02, 2026
🟠 HIGH
Cytosorbents Corporation has been granted a 180-day extension by Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company now has until September 28, 2026, to meet the standard, failing which it may face delisting or be forced to implement a reverse stock split.
🚩 Red Flags
- Chronic non-compliance with Nasdaq listing rules (exceeding 180 days).
- Explicit mention of a potential reverse stock split, which often precedes further share price volatility.
- Risk of delisting if the stock price does not recover organically or through corporate action by September 2026.
📋 Key Facts
- Extension notice received from Nasdaq on April 1, 2026.
- New compliance deadline set for September 28, 2026.
- Original deficiency notice was issued on October 2, 2025, after 30 consecutive business days below $1.00.
- Compliance requires a closing bid price of at least $1.00 for 10 consecutive trading days.
- The company explicitly identified a reverse stock split as a potential option to regain compliance.
📢 Regulation FD Disclosure
Filed Mar 25, 2026
⚪ LOW
Cytosorbents Corporation announced its financial results for the fourth quarter and full year ended December 31, 2025. The announcement was made via a press release on March 25, 2026, and furnished under Items 2.02 and 7.01.
📋 Key Facts
- Reporting period: Quarter and fiscal year ended December 31, 2025.
- Filing date: March 25, 2026.
- The company furnished a press release as Exhibit 99.1.
- The filing was signed by CEO Dr. Phillip P. Chan.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.